Georgia
Provider Communications
Anthem clinical criteria updates for specialty pharmacy are available
Access the clinical criteria document information.
Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by AIM Specialty Health® (AIM), a separate company
- ING-CC-0033 Xolair (omalizumab)
- ING-CC-0043 Monoclonal antibodies to interleukin-5
- ING-CC-0119 Yervoy (ipilimumab)
- ING-CC-0125 Opdivo (nivolumab)
- ING-CC-0157 Padcev (enfortumab vedotin)
- ING-CC-0189 Amondys 45 (casimersen)
- ING-CC-0190 Nulibry (fosdenopterin)
Featured In:
May 2021 Anthem Provider News - Georgia